STERIS
- Home ›
- US ›
- Healthcare
STERIS plc provides infection prevention and other procedural products and services worldwide. The last earnings update was 36 days ago. More info.
Add to Portfolio Compare Print
STE Share Price and Events
7 Day Returns
1 Year Returns
STE Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| STERIS (STE) | 0.8% | 0.8% | 14% | 30.2% | 78.3% | 158% |
| US Medical Equipment | 3.4% | 3.6% | 15% | 20.1% | 71.5% | 99.1% |
| US Market | 2.4% | 1.7% | 11.9% | 1.9% | 38.2% | 42.4% |
1 Year Return vs Industry and Market
- STE outperformed the Medical Equipment industry which returned 20.1% over the past year.
- STE outperformed the Market in United States of America which returned 1.9% over the past year.
Price Volatility
Related Companies
Value
Is STERIS undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
STERIS
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for STERIS.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 9 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 9.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6.7% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.93 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.931 (1 + (1- 19%) (11.96%)) |
1.014 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.01 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.014 * 6.65%) |
9.47% |
Discounted Cash Flow Calculation for NYSE:STE using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for STERIS is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 9.47%) |
|
|---|---|---|---|
| 2019 | 359.35 | Analyst x2 | 328.25 |
| 2020 | 447.23 | Analyst x2 | 373.18 |
| 2021 | 502.01 | Analyst x1 | 382.63 |
| 2022 | 546.71 | Est @ 8.9% | 380.64 |
| 2023 | 585.26 | Est @ 7.05% | 372.22 |
| 2024 | 618.94 | Est @ 5.76% | 359.57 |
| 2025 | 648.95 | Est @ 4.85% | 344.38 |
| 2026 | 676.28 | Est @ 4.21% | 327.83 |
| 2027 | 701.76 | Est @ 3.77% | 310.74 |
| 2028 | 726.02 | Est @ 3.46% | 293.66 |
| Present value of next 10 years cash flows | $3,473.09 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $726.02 × (1 + 2.73%) ÷ (9.47% – 2.73%) |
$11,059.38 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $11,059.38 ÷ (1 + 9.47%)10 |
$4,473.25 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $3,473.09 + $4,473.25 |
$7,946.34 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $7,946.34 / 84.59 |
$93.94 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $93.94 |
| Current discount | Discount to share price of
$123.23
= -1 x ($123.23 - $93.94) / $93.94 |
-31.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of STERIS is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for STERIS's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
STERIS's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $3.18 |
| NYSE:STE Share Price ** | NYSE (2019-03-18) in USD | $123.23 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 63 Publicly-Listed Medical Equipment Companies | 39.02x |
| United States of America Market PE Ratio | Median Figure of 3,055 Publicly-Listed Companies | 17.61x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of STERIS.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:STE Share Price ÷ EPS (both in USD) = 123.23 ÷ 3.18 |
38.79x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- STERIS is good value based on earnings compared to the US Medical Equipment industry average.
- STERIS is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
STERIS's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 38.79x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts |
21.3%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 53 Publicly-Listed Medical Equipment Companies | 2.53x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.48x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 38.79x ÷ 21.3% |
1.82x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- STERIS is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
STERIS's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $36.71 |
| NYSE:STE Share Price * | NYSE (2019-03-18) in USD | $123.23 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 187 Publicly-Listed Medical Equipment Companies | 4.5x |
| United States of America Market PB Ratio | Median Figure of 5,152 Publicly-Listed Companies | 1.87x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:STE Share Price ÷ Book Value per Share (both in USD) = 123.23 ÷ 36.71 |
3.36x |
* Primary Listing of STERIS.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- STERIS is good value based on assets compared to the US Medical Equipment industry average.
Value checks
We assess STERIS's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) STERIS has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is STERIS expected to perform in the next 1 to 3 years based on estimates from 9 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- STERIS's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- STERIS's earnings growth is expected to exceed the United States of America market average.
- STERIS's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:STE Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts | 21.3% |
| NYSE:STE Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts | 5.2% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 20.5% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14.3% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-03-31 | 3,057 | 657 | 441 | 5 |
| 2020-03-31 | 2,899 | 611 | 390 | 9 |
| 2019-03-31 | 2,754 | 523 | 303 | 9 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 2,730 | 490 | 269 |
| 2018-09-30 | 2,696 | 467 | 316 |
| 2018-06-30 | 2,651 | 478 | 303 |
| 2018-03-31 | 2,620 | 458 | 291 |
| 2017-12-31 | 2,585 | 463 | 243 |
| 2017-09-30 | 2,570 | 453 | 144 |
| 2017-06-30 | 2,582 | 424 | 120 |
| 2017-03-31 | 2,613 | 424 | 110 |
| 2016-12-31 | 2,616 | 439 | 142 |
| 2016-09-30 | 2,588 | 364 | 167 |
| 2016-06-30 | 2,431 | 294 | 135 |
| 2016-03-31 | 2,233 | 255 | 111 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
All data from STERIS Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-03-31 | 5.32 | 5.75 | 5.05 | 4.00 |
| 2020-03-31 | 4.71 | 5.25 | 4.49 | 6.00 |
| 2019-03-31 | 3.56 | 3.89 | 3.46 | 6.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 3.18 |
| 2018-09-30 | 3.73 |
| 2018-06-30 | 3.57 |
| 2018-03-31 | 3.42 |
| 2017-12-31 | 2.86 |
| 2017-09-30 | 1.69 |
| 2017-06-30 | 1.40 |
| 2017-03-31 | 1.29 |
| 2016-12-31 | 1.65 |
| 2016-09-30 | 1.99 |
| 2016-06-30 | 1.75 |
| 2016-03-31 | 1.57 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess STERIS's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
STERIS has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has STERIS performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- STERIS has delivered over 20% year on year earnings growth in the past 5 years.
- STERIS's 1-year earnings growth is less than its 5-year average (10.5% vs 20.3%)
- STERIS's earnings growth has not exceeded the US Medical Equipment industry average in the past year (10.5% vs 31.2%).
Earnings and Revenue History
All data from STERIS Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 2,729.93 | 268.90 | 640.61 | 64.77 |
| 2018-09-30 | 2,695.59 | 315.83 | 624.18 | 64.80 |
| 2018-06-30 | 2,650.79 | 302.83 | 615.74 | 63.00 |
| 2018-03-31 | 2,620.00 | 290.92 | 613.67 | 60.78 |
| 2017-12-31 | 2,585.21 | 243.46 | 649.99 | 58.93 |
| 2017-09-30 | 2,570.09 | 143.68 | 630.19 | 58.33 |
| 2017-06-30 | 2,582.34 | 119.64 | 639.99 | 58.97 |
| 2017-03-31 | 2,612.76 | 109.97 | 635.54 | 59.40 |
| 2016-12-31 | 2,616.04 | 141.56 | 522.64 | 57.95 |
| 2016-09-30 | 2,587.96 | 166.60 | 560.09 | 57.69 |
| 2016-06-30 | 2,431.44 | 134.87 | 568.87 | 57.33 |
| 2016-03-31 | 2,232.96 | 110.76 | 543.82 | 56.66 |
| 2015-12-31 | 2,042.22 | 94.42 | 628.98 | 56.53 |
| 2015-09-30 | 1,896.77 | 112.50 | 514.33 | 56.74 |
| 2015-06-30 | 1,869.61 | 134.82 | 468.17 | 55.50 |
| 2015-03-31 | 1,842.35 | 135.06 | 455.02 | 54.14 |
| 2014-12-31 | 1,806.51 | 132.54 | 402.47 | 51.65 |
| 2014-09-30 | 1,738.82 | 122.92 | 435.30 | 48.68 |
| 2014-06-30 | 1,659.85 | 121.66 | 399.66 | 49.20 |
| 2014-03-31 | 1,614.86 | 129.44 | 380.97 | 48.64 |
| 2013-12-31 | 1,585.18 | 131.95 | 375.50 | 48.69 |
| 2013-09-30 | 1,560.04 | 151.54 | 371.76 | 47.52 |
| 2013-06-30 | 1,532.59 | 161.94 | 362.13 | 43.85 |
| 2013-03-31 | 1,501.90 | 159.98 | 354.48 | 41.31 |
| 2012-12-31 | 1,463.94 | 162.77 | 334.54 | 38.67 |
| 2012-09-30 | 1,438.75 | 148.32 | 316.71 | 37.45 |
| 2012-06-30 | 1,425.13 | 137.74 | 312.32 | 36.51 |
| 2012-03-31 | 1,406.81 | 136.12 | 309.55 | 35.95 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- STERIS has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- STERIS used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
- STERIS has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess STERIS's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
STERIS has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is STERIS's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up STERIS's finances.
The net worth of a company is the difference between its assets and liabilities.
- STERIS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- STERIS's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from STERIS Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 3,112.31 | 1,246.31 | 224.91 |
| 2018-09-30 | 3,124.98 | 1,267.72 | 209.92 |
| 2018-06-30 | 3,099.19 | 1,320.06 | 218.52 |
| 2018-03-31 | 3,217.30 | 1,316.00 | 201.53 |
| 2017-12-31 | 3,117.79 | 1,420.05 | 283.84 |
| 2017-09-30 | 3,040.81 | 1,445.30 | 295.63 |
| 2017-06-30 | 2,939.46 | 1,496.47 | 294.84 |
| 2017-03-31 | 2,810.03 | 1,478.36 | 282.92 |
| 2016-12-31 | 2,770.11 | 1,507.04 | 264.86 |
| 2016-09-30 | 3,009.56 | 1,504.19 | 254.35 |
| 2016-06-30 | 3,048.49 | 1,551.84 | 242.42 |
| 2016-03-31 | 3,038.89 | 1,567.80 | 248.84 |
| 2015-12-31 | 2,989.82 | 1,639.46 | 231.36 |
| 2015-09-30 | 1,091.79 | 829.82 | 162.19 |
| 2015-06-30 | 1,099.60 | 686.17 | 196.19 |
| 2015-03-31 | 1,073.65 | 621.08 | 167.69 |
| 2014-12-31 | 1,076.10 | 610.68 | 144.51 |
| 2014-09-30 | 1,067.86 | 619.95 | 147.41 |
| 2014-06-30 | 1,066.00 | 658.74 | 157.94 |
| 2014-03-31 | 1,041.25 | 493.48 | 152.80 |
| 2013-12-31 | 1,009.75 | 474.74 | 157.34 |
| 2013-09-30 | 991.28 | 508.52 | 163.79 |
| 2013-06-30 | 971.27 | 513.70 | 165.84 |
| 2013-03-31 | 946.98 | 492.29 | 142.01 |
| 2012-12-31 | 920.19 | 520.89 | 155.89 |
| 2012-09-30 | 881.63 | 434.34 | 156.61 |
| 2012-06-30 | 833.39 | 210.00 | 186.73 |
| 2012-03-31 | 822.66 | 210.00 | 150.82 |
- STERIS's level of debt (40%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (47% vs 40% today).
- Debt is well covered by operating cash flow (39.3%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 9.6x coverage).
Financial health checks
We assess STERIS's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) STERIS has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is STERIS's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
STERIS
shares you are expected to receive
$22
in your first year as a dividend.
Dividend Amount
- STERIS's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).
- STERIS's dividend is below the markets top 25% of dividend payers in United States of America (3.64%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2004 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-03-31 | 1.59 | 1.00 |
| 2020-03-31 | 1.45 | 3.00 |
| 2019-03-31 | 1.32 | 3.00 |
| Date (Data in $) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-11 | 1.360 | 1.119 |
| 2018-11-06 | 1.360 | 1.205 |
| 2018-08-08 | 1.360 | 1.216 |
| 2018-05-09 | 1.240 | 1.153 |
| 2018-02-07 | 1.240 | 1.335 |
| 2017-08-08 | 1.240 | 1.400 |
| 2017-05-26 | 1.120 | 1.376 |
| 2017-05-09 | 1.120 | 1.479 |
| 2016-11-02 | 1.120 | 1.624 |
| 2016-08-09 | 1.120 | 1.588 |
| 2016-05-18 | 1.000 | 1.448 |
| 2016-02-09 | 1.000 | 1.456 |
| 2015-10-30 | 1.000 | 1.380 |
| 2015-05-07 | 0.920 | 1.387 |
| 2015-02-04 | 0.920 | 1.366 |
| 2014-11-04 | 0.920 | 1.421 |
| 2014-08-08 | 0.840 | 1.496 |
| 2014-08-05 | 0.920 | 1.784 |
| 2014-05-29 | 0.840 | 1.586 |
| 2014-05-08 | 0.840 | 1.575 |
| 2014-02-07 | 0.840 | 1.765 |
| 2014-02-05 | 0.840 | 1.922 |
| 2013-11-08 | 0.840 | 1.797 |
| 2013-10-30 | 0.840 | 1.862 |
| 2013-05-07 | 0.760 | 1.724 |
| 2012-10-31 | 0.760 | 2.045 |
| 2012-08-02 | 0.760 | 2.171 |
| 2012-05-08 | 0.680 | 2.222 |
| 2012-02-07 | 0.680 | 2.177 |
| 2011-11-02 | 0.680 | 2.328 |
| 2011-08-02 | 0.680 | 2.273 |
| 2011-05-09 | 0.600 | 1.707 |
| 2011-02-08 | 0.600 | 1.749 |
| 2010-11-03 | 0.600 | 1.678 |
| 2010-08-03 | 0.600 | 1.869 |
| 2010-05-06 | 0.440 | 1.392 |
| 2010-02-02 | 0.440 | 1.337 |
| 2009-11-03 | 0.440 | 1.484 |
| 2009-07-30 | 0.440 | 1.482 |
| 2009-05-07 | 0.440 | 1.720 |
| 2009-03-20 | 0.320 | 1.345 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Dividends per share have been stable in the past 10 years.
- Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of
STERIS's earnings are
paid
to the shareholders as a dividend.
- Dividends paid are well covered by earnings (2.4x coverage).
- Dividends after 3 years are expected to be well covered by earnings (3.7x coverage).
Income/ dividend checks
We assess STERIS's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can STERIS afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) STERIS has a total score of 4/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $5,205,053 |
| AGE | 64 |
| TENURE AS CEO | 11.4 years |
CEO Bio
Mr. Walter M. Rosebrough, Jr., also known as Walt, has been the Chief Executive Officer and President of STERIS plc since October 1, 2007. Mr. Rosebrough leads STERIS’ management team, assists the Board in its oversight of it and provides unique perspectives into the healthcare industry and its operations, direction and strategies. He joined STERIS in October 2007. Mr. Rosebrough has been a Director of Varex Imaging Corp. since April 20, 2018. From February 2005 to September 2007, Mr. Rosebrough served as the President and Chief Executive Officer of Coastal Hydraulics, Inc., a hydraulic and pneumatic systems company he purchased in 2005, and he continues to serve on its board of directors. He served as the President and Chief Executive Officer of the Hill-Rom Company. He served as an Executive Vice President of Hillenbrand, Inc. He has over 30 years in the healthcare industry in various roles as a senior executive with Hill-Rom Holdings, Inc. (at the time, Hillenbrand Industries, Inc.), a worldwide provider of medical equipment and related services, including President and Chief Executive Officer of Support Systems International. In 2000, he left Hillenbrand to lead Vasocor, Inc., a Credit Suisse First Boston- funded start-up healthcare company, as President and Chief Executive Officer. He was Chief Executive Officer for 25 years. Mr. Rosebrough has leadership experience in many major business functions, including product development, business development, manufacturing, finance, and marketing; experience leading ventures ranging in scale from start-up operations to multi-billion dollar multinational businesses; and Service on the following healthcare industry boards: AAMI (Association for the Advancement of Medical Instrumentation), AdvaMed (Advanced Medical Technology Association), and MDMA (Medical Device Manufacturers Association). He has been a Director of Greater Cleveland Partnership since March 2012. He serves as a Director of Joerns Healthcare. He has been a Director of Steris plc October 1, 2007. He served as a Director for AdvaMed, Health Insights and Margaret Mary Hospital. Mr. Rosebrough holds a Bachelor's degree in Industrial Engineering from Kettering University (Former Name: General Motors Institute) in Flint, Michigan and a Master's degree in Business Administration from Stanford University's Graduate School of Business, in Palo Alto, California.
CEO Compensation
- Walt's compensation has increased by more than 20% in the past year.
- Walt's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the STERIS management team in years:
- The tenure for the STERIS management team is about average.
Management Team
Walt Rosebrough
CEO, President & Director
$5M
64
11.4 yrs
Mike Tokich
Senior VP & CFO
$2M
49
11 yrs
Dan Carestio
Chief Operating Officer
$1M
45
0.6 yrs
John Zangerle
VP, General Counsel & Secretary
$1M
51
5.7 yrs
Adrian Coward
Senior Vice President of Healthcare Specialty Services
$1M
48
3.3 yrs
Karen Burton
Chief Accounting Officer
50
2.2 yrs
Julie Winter
Senior Director of Investor Relations
Kathie Bardwell
Chief Compliance Officer & Senior VP
62
11 yrs
Stephen Norton
Senior Director of Corporate Communications
Michiel de Zwaan
VP & Chief Human Resources Officer
47
1.5 yrs
Board of Directors Tenure
Average tenure and age of the STERIS board of directors in years:
- The average tenure for the STERIS board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Mohsen Sohi
Chairman of the Board
$232K
59
0.7 yrs
Walt Rosebrough
CEO, President & Director
$5M
64
11.4 yrs
Loyal Wilson
Director
$248K
70
32.2 yrs
Richard Breeden
Director
$247K
68
10.9 yrs
David Lewis
Director
$258K
67
8.7 yrs
Richard Steeves
Director
$247K
56
3.3 yrs
Jackie Kosecoff
Director
$238K
69
15.4 yrs
Michael Wood
Director
$232K
74
14.4 yrs
Cynthia Feldmann
Director
$232K
65
14 yrs
Duncan Nichol
Director
$240K
77
3.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 04. Jun 18 | Sell | Walter Rosebrough | Individual | 01. Jun 18 | 01. Jun 18 | -8,571 | $104.46 | $-895,327 | ||
| 31. May 18 | Sell | Walter Rosebrough | Individual | 29. May 18 | 29. May 18 | -10,697 | $102.91 | $-1,100,828 | ||
| 21. May 18 | Sell | Michael Wood | Individual | 18. May 18 | 18. May 18 | -3,800 | $103.51 | $-393,338 | ||
| 14. May 18 | Sell | Karen Burton | Individual | 11. May 18 | 11. May 18 | -1,204 | $102.99 | $-123,700 | ||
Management checks
We assess STERIS's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) STERIS has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
STERIS plc's (NYSE:STE) Earnings Grew 10%, Did It Beat Long-Term Trend?
Below, I will assess STE's latest performance announced on 31 December 2018 and weight these figures against its longer term trend and industry movements. … STE's trailing twelve-month earnings (from 31 December 2018) of US$269m has? … However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 20%, indicating the rate at which STE is growing has slowed down
Simply Wall St - – Full articleSTERIS plc (NYSE:STE): Time For A Financial Health Check
its financial health remains the key to continued success. … I will provide an overview of STERIS’s financial liquidity and leverage to give you an idea of STERIS’s position to take advantage of potential acquisitions or comfortably endure future downturns. … Note that this commentary is very high-level and solely focused on financial health, so I suggest you dig deeper yourself
Simply Wall St - – Full articleTaking A Look At STERIS plc's (NYSE:STE) ROE
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows STERIS has a return on equity of 10% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleHow Financially Strong Is STERIS plc (NYSE:STE)?
STERIS plc (NYSE:STE), a large-cap worth US$10b, comes to mind for investors seeking a strong and reliable stock investment. … Big corporations are much sought after by risk-averse investors who find diversified revenue streams and strong capital returns attractive. … This article will examine STERIS’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth.
Simply Wall St - – Full articleIs STERIS plc's (NYSE:STE) CEO Pay Fair?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big companies. … How Does Walt Rosebrough's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that STERIS plc has a market cap of US$10b, and is paying total annual CEO compensation of US$5.2m
Simply Wall St - – Full articleIs STERIS plc (NYSE:STE) Expensive For A Reason? A Look At The Intrinsic Value
by taking the expected future cash flows and discounting them to their present value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleHere's What STERIS plc's (NYSE:STE) P/E Ratio Is Telling Us
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … To keep it practical, we'll show how STERIS plc's (NYSE:STE) P/E ratio could help you assess the value on offer. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleIs Now The Time To Look At Buying STERIS plc (NYSE:STE)?
saw significant share price volatility over the past couple of months on the NYSE, rising to the highs of $116.75 and falling to the lows of $104.76. … A question to answer is whether STERIS's current trading price of $106.44 reflective of the actual value of the? … Let’s take a look at STERIS’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change
Simply Wall St - – Full articleWant To Invest In STERIS plc (NYSE:STE)? Here's How It Performed Lately
Examining how STERIS plc (NYSE:STE) is performing as a company requires looking at more than just a years' earnings. … Below, I will run you through a simple sense check to build perspective on how STERIS is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its medical equipment industry peers. … Did STE's recent earnings growth beat the long-term trend and the industry.
Simply Wall St - – Full articleHow Confident Are Insiders About STERIS plc (NYSE:STE)?
24.27k shares. … Generally, insiders selling shares in their own firm sends a bearish signal … A research published in The MIT Press (1998) concluded that stocks following insider selling fell 2.7% compared to the market
Simply Wall St - – Full articleCompany Info
Description
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment install, maintain, upgrade, repair, and troubleshoot services. This segment provides its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, including instrument and endoscope repair and maintenance solutions; and custom process improvement consulting and outsourced sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services using gamma, electron beam, and X-ray technologies, as well as ethylene oxide and hydrogen peroxide; and laboratory testing services. It operates a network of approximately 50 facilities. The company was founded in 1985 and is based in Derby, the United Kingdom.
Details
| Name: | STERIS plc |
| STE | |
| Exchange: | NYSE |
| Founded: | 1985 |
| $10,423,710,477 | |
| 84,587,442 | |
| Website: | http://www.steris.com |
| Address: |
STERIS plc Rutherford House, Stephensons Way, Derby, Derbyshire, DE21 6LY, United Kingdom |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | STE | New Common Stock | New York Stock Exchange | US | USD | 01. Jun 1992 | |
| DB | 1S4 | New Common Stock | Deutsche Boerse AG | DE | EUR | 01. Jun 1992 | |
| LSE | 0XI6 | New Common Stock | London Stock Exchange | GB | USD | 01. Jun 1992 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/03/19 00:38 |
| End of day share price update: | 2019/03/18 00:00 |
| Last estimates confirmation: | 2019/03/06 |
| Last earnings filing: | 2019/02/11 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
